Related Experiment Videos
Rapidly Progressive Triple M Overlap Syndrome After Immune Checkpoint Inhibitor Therapy
Seth Garrett1, Anam Ansari2, Sruthi Siddada3
1Internal Medicine, Henry Ford Health System, Detroit, USA.
Cureus
|July 13, 2026
Summary
Triple M overlap syndrome (TMOS) is a rare but fatal complication of immune checkpoint inhibitors (ICIs). Early recognition and aggressive management are crucial before end-organ damage limits treatment options.
Area of Science:
- Oncology
- Immunology
- Neurology
Background:
- Immune checkpoint inhibitors (ICIs) are vital cancer therapies but can induce immune-related adverse events.
- Triple M overlap syndrome (TMOS) is a rare, severe complication characterized by myositis, myocarditis, and myasthenia gravis.
- Metastatic renal cell carcinoma is a challenging diagnosis often treated with combination ICI therapy.
Related Concept Videos
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...